Pediatric Drugs

, Volume 9, Issue 2, pp 71–79

Pharmacologic Management of Glaucoma in Childhood

Leading Article


An evidence-based review of the drugs available for the medical management of childhood glaucoma is presented; almost all of the drugs are not licensed for use in children. Despite this, most topical drugs are safe; however, there are some significant exceptions, such as brimonidine, which may cause apnea, among other life-threatening adverse events, in infants. Broad families of drugs are available including topical adrenoceptor antagonists, topical and systemic carbonic anhydrase inhibitors, prostaglandin analogs, adrenoceptor agonists, parasympathomimetics, and combination preparations. These drugs help to reduce intraocular pressure by reducing aqueous production or increasing the outflow facility.

The variety of anti-ocular hypertensive medications for childhood glaucoma has increased in recent years. The vast majority of data on these medications are from adult studies but each year more experience of their use in pediatric glaucoma is gained. In general, topical treatment is well tolerated; however, the prescribing clinician and carers should be aware of potential adverse effects and how they may present.


  1. 1.
    Taylor D, Hoyt C. Paediatric ophthalmology and strabismus. 3rd ed. London: Elsevier Ltd, 2005Google Scholar
  2. 2.
    Francois J. Congenital glaucoma and its inheritance. Ophthalmologica 1980; 181: 61–73PubMedCrossRefGoogle Scholar
  3. 3.
    Kanski JJ. Clinical ophthalmology: a systematic approach. 5th ed. New York: Butterworth-Heinemann, 2003: 192–269Google Scholar
  4. 4.
    Ho CL, Walton DS. Primary congenital glaucoma: 2004 update. J Pediatr Ophthalmol Strabismus 2004; 41(5): 271–88PubMedGoogle Scholar
  5. 5.
    Doughty MJ, Zaman ML. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol 2000; 44(5): 367–408PubMedCrossRefGoogle Scholar
  6. 6.
    Muir KW, Jin J, Freedman SF. Central corneal thickness and its relationship to intraocular pressure in children. Ophthalmology 2004; 111: 2220–3PubMedCrossRefGoogle Scholar
  7. 7.
    deLuise VP, Anderson DR. Primary infantile glaucoma (congenital glaucoma): review. Surv Ophthalmol 1983; 28(1): 1–19PubMedCrossRefGoogle Scholar
  8. 8.
    Boger 3rd WP, Walton DS. Timolol in uncontrolled childhood glaucomas. Ophthalmology 1981; 88(3): 253–8PubMedGoogle Scholar
  9. 9.
    McMahon CD, Hetherington Jr J, Hoskins Jr HD, et al. Timolol and pediatric glaucomas. Ophthalmology 1981; 88(3): 249–52PubMedGoogle Scholar
  10. 10.
    Hoskins Jr HD, Hetherington Jr J, Magee SD, et al. Clinical experience with timolol in childhood glaucoma. Arch Ophthalmol 1985; 103(8): 1163–5PubMedCrossRefGoogle Scholar
  11. 11.
    Zimmerman TJ, Kooner KS, Morgan KS. Safety and efficacy of timolol in pediatric glaucoma. Surv Ophthalmol 1983; 28(1): 1–19CrossRefGoogle Scholar
  12. 12.
    Weinreb RN, Caldwell DR, Goode SM, et al. A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution. Am J Ophthalmol 1990; 110(2): 189–92PubMedGoogle Scholar
  13. 13.
    Schoene RB, Abuan T, Ward RL, et al. Effects of topical betaxolol, timolol and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol 1984; 97(1): 86–92PubMedGoogle Scholar
  14. 14.
    Diggory P, Cassels-Brown A, Vail A, et al. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet 1995; 345(8970): 1604–6PubMedCrossRefGoogle Scholar
  15. 15.
    Allen RC, Hertzmark E, Walker AM, et al. A double-masked comparison of betaxolol vs timolol in the treatment of open-angle glaucoma. Am J Ophthalmol 1986; 101(5): 535–41PubMedGoogle Scholar
  16. 16.
    Drance SM. A comparison of the effects of betaxolol, timolol and pilocarpine on the visual function in patients with open-angle glaucoma. J Glaucoma 1998; 7(4): 247–52PubMedCrossRefGoogle Scholar
  17. 17.
    British National Formulary. London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society of Great Britain, 2005 SepGoogle Scholar
  18. 18.
    Michaud J-E, Friren B, International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice a day in addition to timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 2001; 132: 235–43PubMedCrossRefGoogle Scholar
  19. 19.
    Portellos M, Buckley E, Freedman S. Topical versus oral carbonic anhydrase inhibitor therapy for paediatric glaucoma. JAAPOS 1998; 2(1): 43–7Google Scholar
  20. 20.
    Silver LH, Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide, a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 1998; 126: 400–8PubMedCrossRefGoogle Scholar
  21. 21.
    Morris S, Geh V, Nischal K. Topical dorzolamide and metabolic acidosis in a neonate. Br J Ophthalmol 2003 Aug; 87(8): 1052–3PubMedCrossRefGoogle Scholar
  22. 22.
    Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999; 127: 403–6PubMedCrossRefGoogle Scholar
  23. 23.
    Holmstrom S, Buchholz P, Walt J, et al. Analytic review of bimatoprost, lata-noprost and travoprost in primary open angle glaucoma. Curr Med Res Opin 2005 Nov; 21(11): 1875–83PubMedCrossRefGoogle Scholar
  24. 24.
    Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol 2002; 47Suppl. 1: S65–76PubMedCrossRefGoogle Scholar
  25. 25.
    Susanna Jr R, Chew P, Kitazawa Y. Current status of prostaglandin therapy: latanoprost and unoprostone. Surv Ophthalmol 2002; 47Suppl. 1: S97–104PubMedCrossRefGoogle Scholar
  26. 26.
    Enyedi LB, Freedman SF. Latanoprost for the treatment of pediatric glaucoma. Surv Ophthalmol 2002; 47Suppl. 1: S129–32PubMedCrossRefGoogle Scholar
  27. 27.
    Ong T, Chia A, Nischal KK. Latanoprost in port wine stain related paediatric glaucoma. Br J Ophthalmol 2003; 87: 1091–3PubMedCrossRefGoogle Scholar
  28. 28.
    Higginbotham EJ, Diestelhorst M, Pfeiffer N, et al. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv Ophthalmol 2002; 47Suppl. 1: S133–40PubMedCrossRefGoogle Scholar
  29. 29.
    Brown S. Increased iris pigment in a child due to latanoprost. Arch Ophthalmol 1998 Dec; 116(12): 1683–4PubMedGoogle Scholar
  30. 30.
    Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002; 47Suppl. 1: S203–18PubMedCrossRefGoogle Scholar
  31. 31.
    Drugs and therapeutics bulletin. The management of primary open angle glaucoma BNF 11.6 1997; 35(1): 4–6 [online]. Available from URL: [Accessed 2006 Feb 21]
  32. 32.
    Drugs and therapeutics bulletin. New topical drugs for open-angle glaucoma. BNF 11.6 2003 (Feb) [online]. Available from URL: [Accessed 2006 Feb 21]
  33. 33.
    Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol 2002; 47Suppl. 1: S219–30PubMedCrossRefGoogle Scholar
  34. 34.
    Levy Y, Zadok D. Systemic side effects of ophthalmic drops. Clin Pediatr 2004; 43(1): 99–101CrossRefGoogle Scholar
  35. 35.
    Carlsen JO, Zabriskie NA, Kwon YH, et al. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol 1999; 128: 255–6PubMedCrossRefGoogle Scholar
  36. 36.
    Mungan NK, Wilson TW, Nischal KK, et al. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers. JAAPOS 2003; 7(1): 69–70Google Scholar
  37. 37.
    Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops in children. Eye 2004; 18(1): 24–6PubMedCrossRefGoogle Scholar
  38. 38.
    Al-Shahwan S, Al-Torbak AA, Turkmani S, et al. Side-effect profile of brimonidine tartrate in children. Ophthalmology 2005; 112: 2143–8PubMedCrossRefGoogle Scholar
  39. 39.
    Schwartzenberg GW, Buys YM. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy. Ophthalmology 1999; 106: 1616–20CrossRefGoogle Scholar
  40. 40.
    Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 1998; 105: 1936–44PubMedCrossRefGoogle Scholar
  41. 41.
    Goni FJ. 12-week study comparing the fixed combination of brimonidine and timolol with its concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005; 15: 581–90PubMedGoogle Scholar
  42. 42.
    Patton TF, Robinson JR. Pediatric dosing considerations in ophthalmology. J Ped Ophthalmol 1976; 13(3): 171–8Google Scholar
  43. 43.
    Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol 1982; 26: 207–18PubMedCrossRefGoogle Scholar
  44. 44.
    Passo MS, Palmer EA, Van-Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology 1984; 91(11): 1361–3PubMedGoogle Scholar
  45. 45.
    Palmer EA. How safe are ocular drugs in pediatrics? Ophthalmology 1986; 93(8): 1038–40PubMedGoogle Scholar
  46. 46.
    Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86: 418–23PubMedCrossRefGoogle Scholar
  47. 47.
    Baudouin CB, Pisella P-J, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs. Ophthalmology 1999; 106: 556–63PubMedCrossRefGoogle Scholar
  48. 48.
    Lavin MJ, Wormald RP, Migdal CS, et al. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990; 108(11): 1543–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Department of OphthalmologyGreat Ormond Street Hospital for ChildrenLondonEngland
  2. 2.Visual Sciences UnitInstitute of Child HealthLondonEngland
  3. 3.Department of Clinical and Academic OphthalmologyGreat Ormond Street Hospital for ChildrenLondonEngland

Personalised recommendations